Abstract:Major Depressive Disorder (MDD) is a common, frequently chronic condition characterized by substantial molecular alterations and pathway dysregulations. Single metabolite and targeted metabolomics platforms have revealed several metabolic alterations in depression, including energy metabolism, neurotransmission, and lipid metabolism. More comprehensive coverage of the metabolome is needed to further specify metabolic dysregulations in depression and reveal previously untargeted mechanisms. Here, we measured 820 metabolites using the metabolome-wide Metabolon platform in 2770 subjects from a large Dutch clinical cohort with extensive clinical phenotyping (1101 current MDD, 868 remitted MDD, 801 healthy controls) at baseline, which were repeated in 1805 subjects at 6-year follow up (327 current MDD, 1045 remitted MDD, 433 healthy controls). MDD diagnosis was based on DSM-IV psychiatric interviews. Depression severity was measured with the Inventory of Depressive Symptomatology Self-report. Associations between metabolites and MDD status and depression severity were assessed at baseline and at 6-year follow-up. At baseline, 139 and 126 metabolites were associated with current MDD status and depression severity, respectively, with 79 overlapping metabolites. Adding body mass index and lipid-lowering medication to the models changed results only marginally. Among the overlapping metabolites, 34 were confirmed in internal replication analyses using 6-year follow-up data. Downregulated metabolites were enriched with long-chain monounsaturated ( P = 6.7e−07) and saturated ( P = 3.2e−05) fatty acids; upregulated metabolites were enriched with lysophospholipids ( P = 3.4e−4). Mendelian randomization analyses using genetic instruments for metabolites ( N = 14,000) and MDD ( N = 800,000) showed that genetically predicted higher levels of the lysophospholipid 1-linoleoyl-GPE (18:2) were associated with greater risk of depression. The identified metabolome-wide profile of depression indicated altered lipid metabolism with downregulation of long-chain fatty acids and upregulation of lysophospholipids, for which causal involvement was suggested using genetic tools. This metabolomics signature offers a window on depression pathophysiology and a potential access point for the development of novel therapeutic approaches.

Dissection of depression heterogeneity using proteomic clusters

Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study

A network analysis of depressive symptoms and metabolomics

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

The metabolome-wide signature of major depressive disorder

Plasma Disturbance of Phospholipid Metabolism in Major Depressive Disorder by Integration of Proteomics and Metabolomics

Distinct proteomic profiles in prefrontal subareas of elderly major depressive disorder and bipolar disorder patients

Background data for the identification of protein biomarkers in CSF by proteomic approaches

Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts

Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients

Dissecting depression symptoms: multi-omics clustering uncovers immune-related subgroups and cell-type specific dysregulation

Symptom clustering of major depression in a national telehealth sample

Correlating plasma protein profiles with symptomatology and treatment response in acute phase and early remission of major depressive disorder

Network analysis of plasma proteomes in affective disorders

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

Biological heterogeneity of melancholia: Results of pattern recognition methods

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

Identification of novel endoplasmic reticulum-related genes and their association with immune cell infiltration in major depressive disorder

Using network analysis to examine links between individual depressive symptoms, inflammatory markers, and covariates

Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials